Amyotrophic Lateral Sclerosis (ALS) is a progressive fatal neurodegenerative disease affecting motor neurons. Early diagnosis is essential for the success of clinical trials and objective biomarkers are needed for monitoring disease progression. Nerve and muscle ultrasound may provide this information. This study will collect pilot data to evaluate the value of muscle and nerve ultrasound to identify and monitor disease progression in ALS.
Study Type
OBSERVATIONAL
Enrollment
40
Ultrasound of 6 muscles and 2 nerves will be performed.
Duke University Medical Center
Durham, North Carolina, United States
Abnormalities at onset: Ultrasound vs. Electromyography
Ultrasound measures will be compared to electromyography measures at the patient's initial assessment. The number of abnormal muscles will be counted using each technique and analyzed to determine if one test is superior.
Time frame: 1 year
Ultrasound Predicting Outcome at 1 year
The initial ultrasound measures and patient outcomes, as measured by standard validated scales, will be assessed at periodic intervals for one year. Analysis will be performed to determine if ultrasound measures can predict the clinical course.
Time frame: 1.5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.